Navigation Links
Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
Date:8/23/2007

SAN DIEGO, Aug. 23 /PRNewswire/ -- eBioscience Corporation announced the appointment of Todd R. Nelson, Ph.D., to CEO of eBioscience, effective immediately. Dr. Nelson comes to eBioscience from Invitrogen Corporation where he was Vice President, Global Corporate Development.

Dr. Nelson will assume the role of CEO and Lily Lai, eBioscience's founder, will remain as President during a transition period. Nelson will also join eBioscience's Board of Directors.

Dr. Nelson commented: "I'm very excited about joining a fast growing company with the reputation and potential of eBioscience. The company's breakthrough products and enabling technologies are critical to the future of biotechnology and life science research."

Dr. Brian Seed, the Lead Director on eBioscience's Board of Directors, commented: "Todd has exceptional technical, financial and operating experience, and the energy and strategic vision to lead eBioscience through its next stage of growth."

Seed continued: "During Lily's tenure as President, eBioscience has grown from a start-up enterprise to a fast growing, profitable company that now has more than 1,000 products on the market, and a strong brand within the life science research community. We are grateful for her many contributions to eBioscience."

Todd R. Nelson was named Vice President Global Corporate Development and Strategy of Invitrogen Corporation in 2005. In addition to being responsible for mergers and acquisitions functions globally, Nelson held primary responsibility for the development and implementation of both corporate and divisional strategies for the organization on a world wide basis. Prior to that, he was Managing Director and Head, Global Life Sciences Corporate Strategy and Research at RBC Capital Markets, and First Vice President, Global Corporate Strategy and Economics at Merrill Lynch in New York.

Dr. Nelson has been a visible figure within the Life Sciences industry. During his more than 15 year tenure in the industry he has been responsible for the design and implementation of numerous corporate and operating strategies for various companies. In addition, he led the underwriting activities for more than 30 IPOs and has been involved in numerous value creating mergers and acquisitions, together totaling more than $7 billion. He has been a founder of several biotechnology companies and currently serves on the Board of Directors of Lokoya Capital Partners, LLC. Fluoropharma, Inc., and Blue Heron Biotechnologies, Inc.

Dr. Nelson has a Ph.D. from the University of Minnesota in molecular pathology and received advanced training as a senior fellow in clinical chemistry and molecular diagnostics at Mayo Clinic. Dr. Nelson received his MBA from the Carlson School of Business.

About eBioscience

eBioscience, headquartered in San Diego, California provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide. The company provides essential life science technologies for disease research and drug discovery. For more information, visit http://www.ebioscience.com.


'/>"/>
SOURCE eBioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Visions: Innovating like Madonna and Willie Nelson (and Steve Jobs)
2. Bruce Maas named CIO at UW-Milwaukee
3. Three finalists named for UW-Madison CIO
4. Eight lawmakers named to Speakers IT task force
5. Hospital named for Madame Curie installs TomoTherapy system
6. Two UW-Madison professors named to National LambdaRail Networking Research Council
7. UW researcher named top innovator
8. Alzheimers drug firm and more winners named in Wisconsin business-plan contest
9. Inacom named Microsofts favorite learning solutions partner of the year
10. Five Wisconsin CIOs named top in nation
11. Deltanoid named to top-15 list of biotech companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... This CAST literature ... for biotech crops. The authors focus on the economic effects in countries that are ... of new biotech crops and the resultant risk of low level presence (LLP) puts ...
(Date:12/8/2016)... HOWELL, N.J. , Dec. 8, 2016 /PRNewswire/ ... aquatic augmentation remediation technologies and selected NewTechBio,s NT-MAX ... , a microbial based beneficial bacteria, in conjunction ... Inc., to correct deficiencies with National Pollutant Discharge ... basin 281-8H has experienced a steady history of ...
(Date:12/7/2016)... Diego (PRWEB) , ... December 07, 2016 , ... ... data from its phase I/II dose escalation and expansion clinical trial for its ... in Vienna, Austria. The purpose of the trial was to determine the safety, ...
(Date:12/7/2016)... , Dec. 7, 2016 /PRNewswire/ - OncoQuest ... development and commercialization of immunotherapeutic products for the ... entered into an Antibody Manufacturing Development Program with ... , USA) for its oregovomab antibody product. Supported ... Phase IIb clinical study in ovarian cancer patients, ...
Breaking Biology Technology:
(Date:12/5/2016)...  The Office of Justice Programs, National Institute ... Enhance or Replace Medico Legal Autopsies?" on NIJ.gov.  ... replacing forensic autopsies with postmortem X-ray computed tomography, ... response to recommendations made by The National Academy ... as a potential component of medicolegal death investigations. ...
(Date:11/30/2016)... 30, 2016 Not many of us realize that we spend ? of ... we need to do it well. Inadequate sleep levels have been found to lead ... diabetes, and even cancer. Maybe now is the best time to rethink ... them to manage their sleep quality? Continue Reading ... ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
Breaking Biology News(10 mins):